[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345162-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345162-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","disparities-in-blood-cancer-survival-in-the-uk-20092019-national-cohort-studies","Disparities in blood cancer survival in the UK 2009–2019: national cohort studies","","Blood cancers are among the most common and deadliest cancers in the UK, with survival varying across subtypes, yet UK nations have lacked routine, population-level reporting by finer clinical and demographic factors. This study estimated 1-, 5-, and 10-year net survival for haematological malignancies using four retrospective national cohorts from cancer registries across 2009–2019. Survival differed by subtype and demographics, including notable sex, age, deprivation, ethnicity, and rurality patterns, with Scotland not showing overall improvement.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/disparities-in-blood-cancer-survival-in-the-uk-20092019-national-cohort-studies/345162/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/disparities-in-blood-cancer-survival-in-the-uk-20092019-national-cohort-studies/345162.png","ImageObject",300,407,{"name":42,"@type":43},"Maeve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What time period and data sources were used to estimate survival?","Question",{"text":63,"@type":64},"The study used four retrospective cohorts of patients aged 15–99 diagnosed with haematological malignancies across UK cancer registries during 2009–2019.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did survival change across UK nations from 2009–2019?",{"text":68,"@type":64},"Survival for all blood cancer combined improved significantly in England, Northern Ireland, and Wales, while it did not improve in Scotland.",{"name":70,"@type":61,"acceptedAnswer":71},"Which demographic factors were linked to differences in net survival?",{"text":72,"@type":64},"Older age and higher deprivation were associated with lower survival. Sex differences were also seen across many subtypes, and additional patterns emerged for ethnicity in England and rurality in Wales.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345162,1790201515,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","[www.nature.com/bjcreports](www.nature.com/bjcreports)  \nARTICLE OPEN   \nDisparities in blood cancer survival in the UK 2009–2019: national cohort studies  \nJanice Hoang 1 ✉ , Joshua Allen2, Rebecca Capel2, Rebecca Thomas3, Stephanie Smits4, Rubina Ahmed5, Hilary Webb5, Aziz Sheikh6, Sally Cox2, Ceri Bygrave7 and Julia Hippisley-Cox8  \n© The Author(s) 2026  \nBACKGROUND: Blood cancers are among the most common and deadliest in the UK, affecting over 40,000 people annually. Survival varies by subtype, but this is not routinely reported for the UK. This study estimated survival for haematological malignancies in the UK stratiﬁed by time period, age, sex, ethnicity, deprivation, and rurality.  \nMETHODS: Four retrospective cohorts of patients aged 15–99 diagnosed with haematological malignancies (2009–2019) across UK cancer registries were used to estimate 1-, 5-, and 10-year net survival by subtype.  \nRESULTS: We identiﬁed 413,286 blood cancer cases. Survival in all blood cancer combined signiﬁcantly improved in England (3.8%), Northern Ireland (5.1%), and Wales (3%), but not Scotland. Men had ≥3% lower survival than women in many subtypes. Older age and higher deprivation were signiﬁcantly linked to lower survival. In England, white ethnic groups had ≥3% lower survival than non-white groups for myelodysplastic syndrome, myeloid malignancies, plasma cell neoplasms, myeloproliferative neoplasms. In Wales, rural areas showed ≥3% higher survival than urban and mixed regions for lymphoid malignancies, myeloid malignancies, plasma cell neoplasms, Hodgkin lymphoma, mature B-cell neoplasms, acute myeloid leukaemia.  \nCONCLUSION: Net survival varied markedly by subtype and demographic factors across the UK. Given possible differences in case ascertainment, ﬁndings are descriptive and hypothesis‑generating.  \nBJC Reports; [https://doi.org/10.1038/s44276-026-00222-0](https://doi.org/10.1038/s44276-026-00222-0)  \nINTRODUCTION  \nBlood cancers are among the most commonly diagnosed cancer types and rank as one of the leading causes of cancer-related deaths in the UK [1], affecting over 40,000 people each year [2] . Blood cancer survival varies signiﬁcantly by subtype. For example, population‑based European registry studies report substantial variation in 5‑year survival, with estimates around 50–55% for myeloma and leukaemia, and over 80% for Hodgkin lymphoma [3] . Prior research has focused on reporting survival for speciﬁc groups, namely lymphoid neoplasms [4] and myeloid malignancies [5] . Additionally, routine national reporting typically only focuses on high-level categories i.e. HL, myeloid leukaemia, nonHL, limiting insights into more granular patterns [6] . Although survival for blood cancers has improved over recent decades [3], there have been limited analyses of differences in survival from blood cancers by factors such as age, sex, ethnicity, region and deprivation within the UK. Evidence from other countries and cancer types suggests that disparities likely exist [3, 7–9] . Consistent with this, evidence from the UK also demonstrates socioeconomic and disease-speciﬁc differences in cancer survival, including in haematological malignancies [10–13] .  \nLarge-scale, population-based information on the survival of patients from all hematologic malignancies (HM) according to the  \nWorld Health Organization (WHO) Classiﬁcation, the International Classiﬁcation of Diseases for Oncology (ICD-O), or HAEMACARE groupings, remains scarce and is not routinely reported within the UK nations. The HAEMACARE groupings, a European initiative, grounded in the WHO classiﬁcation/ICD-O-3, aimed to harmonise and improve the comparability of population-based data on HM across registries [14] . These groupings align with efforts by the International Lymphoma Epidemiology Consortium for lymphoid neoplasms and remain consistent with WHO principles [15] .  \nAlthough the HAEMACARE classiﬁcation is based on earlier WHO and ICD-O-3 standards, several updates have","cbCaiew0qxwIl46Q","https://ap.wps.com/l/cbCaiew0qxwIl46Q","pdf",478914,"English","# Introduction\n## Background and rationale\n## Rationale for classification approach\n## Importance of examining subtypes and disparities\n# Methods\n## Retrospective cohort design and data sources\n## Survival estimation (1-, 5-, 10-year net survival)\n# Results\n## Overall survival trends by UK nation\n## Associations with sex, age, deprivation\n## Differences by ethnicity and rurality\n# Conclusion","[{\"question\":\"What time period and data sources were used to estimate survival?\",\"answer\":\"The study used four retrospective cohorts of patients aged 15–99 diagnosed with haematological malignancies across UK cancer registries during 2009–2019.\"},{\"question\":\"How did survival change across UK nations from 2009–2019?\",\"answer\":\"Survival for all blood cancer combined improved significantly in England, Northern Ireland, and Wales, while it did not improve in Scotland.\"},{\"question\":\"Which demographic factors were linked to differences in net survival?\",\"answer\":\"Older age and higher deprivation were associated with lower survival. Sex differences were also seen across many subtypes, and additional patterns emerged for ethnicity in England and rurality in Wales.\"}]","Disparities in blood cancer survival in the UK 2009–2019: national cohort studies | PDF",1790056684,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6680e27ec7166980e69116e6013133a5.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70ff5e9d60d70577c797cf30dfdc861f.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73ed8349d0a61e446cbbdd91728d45d8.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99c3f93bb30b762490cfb22f547cfe05.webp",980,1301]